Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06560502 · ClinicalTrials.gov registry record · NA
Modified Multi-Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of DFU and VLUs
A NA study of Diabetic Foot Ulcer and Venous Leg Ulcer, sponsored by Stability Biologics.
- Recruiting
- Registry status
- NA
- Development phase
- 324
- Enrollment target
- 1
- Study location
NCT06560502: Recruiting NA study of Diabetic Foot Ulcer and Venous Leg Ulcer, sponsored by Stability Biologics.
NCT06560502 is a NA study of Diabetic Foot Ulcer and Venous Leg Ulcer that is actively recruiting participants, run by Stability Biologics. The registered enrollment target is 324 participants, above the 250-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06560502, a NA study of Diabetic Foot Ulcer and Venous Leg Ulcer, is actively recruiting participants, sponsored by Stability Biologics.
- RECRUITING
- Registry status
- NA
- Development phase
- 324 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multicenter, prospective, randomized controlled modified multi-platform (matriarch) trial evaluating several cellular, acellular, and matrix-like products (CAMPs) and standard of care versus standard of care alone in the management of nonhealing diabetic foot and venous leg ulcers.
Primary Outcome
To determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing diabetic foot ulcers and venous leg ulcers with multiple CAMPs plus SOC versus SOC alone over 12 weeks using a modified dual platform (Matriarch) trial design.
Conditions Studied
Interventions
- OTHER Standard of Care-DFU
- OTHER AmnioCore - DFU
- OTHER Amnio Quad-Core - DFU
- OTHER Standard of Care-VLU
- OTHER Amnio Tri-Core - VLU
Study Locations (1)
Ohio
- Cutting Edge Research - Circleville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT06560502 shows while recruiting
NCT06560502 is an interventional study that assigns participants to a tested intervention. The registered 324 participants enrollment target is mid-sized for trials with a published cap, above the 250-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (30% higher).
The record links to 4 conditions, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 5 interventions - of which Standard of Care-DFU is the first listed.
NCT06560502 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06560502 about?
NCT06560502 is a clinical study titled "Modified Multi-Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of DFU and VLUs". This is a multicenter, prospective, randomized controlled modified multi-platform (matriarch) trial evaluating several cellular, acellular, and matrix-like products (CAMPs) and standard of care versus standard of care alone in the management of nonhealing diabetic foot and venous leg ulcers.
What is the current status of trial NCT06560502?
This trial is currently recruiting. It is a NA study. The enrollment target is 324 participants. The study started on 2024-08-01. Estimated completion is 2026-08.
What conditions does trial NCT06560502 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer, Venous Leg Ulcer, Ulcer Foot, Leg Ulcer.
What interventions are being tested in trial NCT06560502?
The interventions under investigation include: Standard of Care-DFU (OTHER), AmnioCore - DFU (OTHER), Amnio Quad-Core - DFU (OTHER), Standard of Care-VLU (OTHER), Amnio Tri-Core - VLU (OTHER).
Who is sponsoring clinical trial NCT06560502?
This trial is sponsored by Stability Biologics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06560502 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06560502's enrollment target sits among peer trials
324 10th of 67 higher than 58 of 67 other Diabetic Foot Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
-
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
RECRUITING · NA
-
Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
RECRUITING · NA
-
Exercise Enhances Wound Healing in Patients With Diabetic Foot Ulcers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI